Brought to you by 
Cardiome grants Eddingpharm Brinavess license in some Asian countries
23 Jul 2019
Executive Summary
Cardiome Pharma Corp. licensed Eddingpharm International Holdings Ltd. rights in China, Taiwan, and Macau to develop and commercialize Brinavess (vernakalant intravenous) for atrial fibrillation and to re-launch the product in Hong Kong.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Cardiome grants Eddingpharm Brinavess license in some Asian countries
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice